PMGC Holdings (ELAB) Other Non-Current Assets (2022 - 2024)

PMGC Holdings (ELAB) posted Other Non-Current Assets of $10773.0 for Q2 2024, little changed sequentially from $10773.0 in Q1 2024.

PMGC Holdings (ELAB) Other Non-Current Assets (2022 - 2024) Analysis & Trends

PMGC Holdings has reported Other Non-Current Assets for 3 years, with the latest figure at $10773.0 in Q2 2024.

Quarterly Other Non-Current Assets changed N/A year-over-year to $10773.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $10773.0 (changed N/A YoY) and the FY2023 annual result came in at $10773.0, changed 0.0% from the prior year.
Other Non-Current Assets steadied at $10773.0 in Q2 2024 per ELAB's latest filing, from $10773.0 in the prior quarter.
Over five years, Other Non-Current Assets peaked at $10.8 million in Q3 2023 and troughed at $10773.0 in Q4 2022.
A 3-year average of $2.2 million and a median of $10773.0 in 2022 frame the typical range for Other Non-Current Assets.
The widest YoY moves for Other Non-Current Assets: up 0.0% in 2023, down 0.0% in 2023.
Over 3 years, Other Non-Current Assets stood at $10773.0 in 2022, then changed by 0.0% to $10773.0 in 2023, then changed by 0.0% to $10773.0 in 2024.
According to Business Quant data, Other Non-Current Assets over the past three periods registered $10773.0, $10773.0, and $10773.0 for Q2 2024, Q1 2024, and Q4 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Other Non-Current Assets (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	1.25 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	2.31 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	124.00 Mn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	618.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	109.58 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	65.13 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	202.31 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	104.44 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	62.96 Mn
10	PMGC Holdings	31.22 Mn	12.43 Mn	385,691.00	-

Download Data